The Union Cabinet chaired by the Prime Minister, Shri Narendra Modi has given its approval to introduce the Production-Linked Incentive (PLI) Scheme in the 10 key sectors for Enhancing
India’s Manufacturing Capabilities and Enhancing Exports – Atmanirbhar Bharat.
Objective: The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs.
Quantum of Incentive: Financial incentive under the scheme shall be provided on sales of 41 identified products for six (06) years at the rates given below:
| Years | Fermentation Based | Chemical Synthesis Based |
| FY 2022-23 | NA | 10% |
| FY 2023-24 to FY 2026-27 | 20% | 10% |
| FY 2027-28 | 15% | 10% |
| FY 2028-29 | 5% | NA |
Tenure of the scheme: The tenure of the scheme is from FY 2020-21 to FY 2029-30.
List of eligible targeted segments covering above products:
Fermentation based KSMs/Drug Intermediates
- Penicillin G
- 7-ACA
- Erythromycin Thiocyanate(TIOC)
- Clavulanic
Fermentation based niche KSMs/Drug Intermidiates/APIs
- Neomycin
- Gentamycin
- Betamethasone
- Dexamethasone
- Prednisolone
- Rifampicin
- Vitamin B1
- Clindamycin base
- Streptomycin
- Tetracyclin
Key Chemical Synthesis based KSMs/Drug Intermediates
- 1,1 Cyclohexane Diacetic Acid (CDA)
- 2-Methyl-5Nitro-Imidazole (2-MNI)
- Dicyandiamide (DCDA)
- Para amino phenol
Other Chemical Synthesis based KSMs/Drug Intermediates/APIs
- Meropenem
- Atrovastatin
- Olmesartan
- Valsartan
- Losartan
- Levofloxacin
- Sulfadiazine
- Ciprofloxacin
- Ofloxacin
- Norfloxacin
- Artesunate
- Telmisartan
- Aspirin
- Diclofenac Sodium
- Levetiracetam
- Carbidopa
- Ritonavir
- Lopinavir
- Acyclovir
- Carbamazepine
- Oxcarbazepine
- Vitamin B6
- Levodopa
Eligible threshold criteria:
List of Eligible & identified products:
For more queries, you can write us on rajnikant@rmpsco.com
Published on: May 4, 2021